Ensuring patients around the world have access to plasma-derived medicines requires collaboration, innovation, and sustained advocacy. In 2025, the plasma industry made meaningful progress across each of these areas, strengthening the systems that support both donors and patients who rely on plasma-derived medicinal products (PDMPs).
This past year saw important advancements in regulatory engagement, policy awareness, and global collaboration. Industry leaders worked closely with policymakers to improve understanding of the unique characteristics of plasma-derived medicines, including their complex manufacturing processes, long production timelines, and reliance on consistent plasma donation from healthy donors.
Equally important were efforts to support donor health and safety. Continuous improvements in screening, monitoring, and operational practices reinforced the industry’s commitment to protecting plasma donors, which is the foundation of the entire plasma ecosystem. Without donors, lifesaving therapies for immune disorders, bleeding conditions, neurological diseases, and other serious health conditions would not exist.
These milestones represent more than organizational achievements; they reflect progress toward a more resilient and sustainable global plasma supply chain that patients depend on every day.
Explore more insights and updates on the plasma industry at PPTA Global and read PPTA's 2025 Annual Report.